MCC950 treatment significantly alleviated NLRP3, Caspase-1 and IL-1β protein overexpression in ankle joint tissues of gout model mice compared with vehicle-treated (control) group (Fig. 4C–E), confirming the effectiveness of MCC950 on NLRP3 inflammasome. This evidence concerns the gene IL1B and gout.